ArticleThorax2006
Non-tuberculous mycobacteria in end stage cystic fibrosis: implications for lung transplantation.
Article in Thorax, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 166 citations in OpenAlex.
- Guideline
- The Epidemiology of Nontuberculous Mycobacteria in Cystic Fibrosis.Children (Basel, Switzerland) · 2025Review
- Single-lung Transplant in a Patient with Mycobacterium avium Pulmonary Disease Successfully Treated with Amikacin Liposome Inhalation Suspension.Internal medicine (Tokyo, Japan) · 2025Article
- A narrative review on the management of patients awaiting lung transplantation in Japan.Journal of thoracic disease · 2023Review
- Lung Transplantation in a New Era in the Field of Cystic Fibrosis.Life (Basel, Switzerland) · 2023Review
- Management of nontuberculous mycobacteria in lung transplant cases: an international Delphi study.ERJ open research · 2023Article
- Diagnosis and Management of Pulmonary NTM with a Focus onMicroorganisms · 2022Review
- Recipient Management before Lung Transplantation.Journal of chest surgery · 2022Article
- Current trends in candidate selection, contraindications, and indications for lung transplantation.Journal of thoracic disease · 2021Review
- Epidemiology, diagnosis & treatment of non-tuberculous mycobacterial diseases.The Indian journal of medical research · 2020Review
- Cross-transmission Is Not the Source of New Mycobacterium abscessus Infections in a Multicenter Cohort of Cystic Fibrosis Patients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Lung transplant referral for individuals with cystic fibrosis: Cystic Fibrosis Foundation consensus guidelines.Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2019Review
- NonTuberculous Mycobacteria infection and lung transplantation in cystic fibrosis: a worldwide survey of clinical practice.BMC pulmonary medicine · 2018Article
- Non-tuberculous Mycobacterial Infections in Thoracic Transplant Candidates and Recipients.Current infectious disease reports · 2018Review
- Host Variability in NTM Disease: Implications for Research Needs.Frontiers in microbiology · 2018Review
- Bacterial infections in patients with primary ciliary dyskinesia: Comparison with cystic fibrosis.Chronic respiratory disease · 2017Review
- Pediatric lung transplantation.Journal of thoracic disease · 2017Review
- Non-tuberculous mycobacterial infections in solid organ transplant recipients: An update.Journal of clinical tuberculosis and other mycobacterial diseases · 2016Review
- Nontuberculous Mycobacteria in Cystic Fibrosis.Current treatment options in infectious diseases · 2016Review
- Lung transplantation for cystic fibrosis: results, indications, complications, and controversies.Seminars in respiratory and critical care medicine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundWC and NS contributed equally. Non-tuberculous mycobacteria (NTM) frequently colonise patients with end stage cystic fibrosis (CF), but its impact on the course of the disease following lung transplantation is unknown.
methodsLung transplant recipients with CF who underwent lung transplantation at our institution between January 1990 and May 2003 (n=146) and CF patients awaiting lung transplantation in May 2003 (n=31) were studied retrospectively.
resultsThe prevalence rate of NTM isolated from respiratory cultures in patients with end stage CF referred for lung transplantation was 19.7%, compared with a prevalence rate of 13.7% for NTM isolates in CF lung transplant recipients. The overall prevalence of invasive NTM disease after lung transplantation was low (3.4%) and was predicted most strongly by pre-transplant NTM isolation (p=0.001, Fisher's exact test, odds ratio (OR) 6.13, 95% CI 3.2 to 11.4). This association was restricted to Mycobacterium abscessus (p = 0.005, Fisher's exact test, OR 7.45, 95% CI 2.9 to 16.9). While NTM disease caused significant morbidity in a small number of patients after transplantation, it was successfully treated and did not influence the post-transplant course of the disease.
conclusionThe isolation of NTM before transplantation in CF patients should not be an exclusion criterion for lung transplantation, but it may alert the clinician to patients at risk of recurrence following transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.